Marksans Pharma Adjusts Valuation Amid Strong Financial Metrics and Growth Challenges

Marksans Pharma, a midcap player in the Pharmaceuticals & Drugs industry, has recently undergone an adjustment in its evaluation. This revision reflects a shift in its valuation grade, moving from a classification of very expensive to expensive.
Key financial metrics indicate that the company maintains a PE ratio of 26.88 and a price-to-book value of 4.34, suggesting a premium positioning in the market. The enterprise value to EBITDA stands at 18.40, while the EV to EBIT is recorded at 21.88. Additionally, the PEG ratio is noted at 1.67, which provides insight into the company's growth relative to its valuation.

Marksans Pharma has demonstrated strong management efficiency, highlighted by a return on equity (ROE) of 15.21% and a return on capital employed (ROCE) of 23.44%. The company has also reported significant net sales, reaching Rs 681.85 crore in the latest quarter, alongside a robust institutional holding of 26.76%.

Despite these positive indicators, the company has faced challenges in long-term growth, with operating profit increasing at an annual rate of 5.08% over the past five years.

For more insights on Marksans Pharma's financial trend performance, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.